Want to see ES:ATRY full AI Analyst Report?
ATRY Stock Chart & Stats
€3.01
-€0.02(-0.59%)
At close: 4:00 PM EST
€3.01
-€0.02(-0.59%)
Day’s Range― - ―
52-Week Range€2.51 - €3.59
Previous CloseN/A
Volume990.00
Average Volume (3M)83.73K
Market Cap
€192.61M
Enterprise Value€449.02M
Total Cash (Recent Filing)€17.76M
Total Debt (Recent Filing)€257.87M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding76,014,190
10 Day Avg. Volume190,561
30 Day Avg. Volume83,732
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.47
Price to Sales (P/S)1.58
P/FCF Ratio-15.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside66.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)€172.80M
Bulls Say, Bears Say
Bulls Say
Recurring Contract-based RevenueAtrys' business benefits from multi-year service agreements with hospitals and health systems, providing recurring revenue and predictable clinical volume streams. This durable contract structure supports revenue visibility, client retention and phased capital allocation across diagnostic and radiotherapy assets over months.
Diversified Clinical Services MixA diversified portfolio—radiation oncology, diagnostic imaging, telemedicine and prevention programs—creates multiple durable revenue channels. Structural demand for cancer diagnosis/treatment and remote clinical services supports steady volumes and cross-sell, reducing reliance on any single service line.
Manageable Historical LeverageHistorically moderate debt (generally below 1x equity) and stable total debt provide balance-sheet headroom. Manageable leverage lowers short-term refinancing pressure, preserving optionality to access capital if needed to bridge operations or invest selectively while addressing cash-flow volatility.
Bears Say
Sharp Revenue Contraction In 2025A material revenue decline in 2025 reduces operational scale and impairs fixed-cost absorption across capital-intensive radiotherapy and imaging services. Sustained lower volumes would weaken unit economics, pressure margins and complicate recovery planning over the next several months.
Persistent Negative Free Cash FlowConsistently negative free cash flow, with a worse outcome in 2025, signals ongoing cash burn and reliance on financing or balance-sheet resources. Over 2–6 months this limits reinvestment in equipment or growth, increases funding risk and pressures liquidity management.
Ongoing Operating Losses Eroding EquitySustained operating losses and worsening 2025 results are eroding shareholder equity and producing negative ROE. Continued losses constrain the ability to self-fund growth, raise dilution risk from future capital raises, and undermine long-term profitability prospects absent structural recovery.
Atrys Health SA News
ATRY FAQ
What was Atrys Health SA’s price range in the past 12 months?
Atrys Health SA lowest stock price was €2.51 and its highest was €3.59 in the past 12 months.
What is Atrys Health SA’s market cap?
Atrys Health SA’s market cap is €192.61M.
When is Atrys Health SA’s upcoming earnings report date?
Atrys Health SA’s upcoming earnings report date is Aug 05, 2026 which is in 34 days.
How were Atrys Health SA’s earnings last quarter?
Currently, no data Available
Is Atrys Health SA overvalued?
According to Wall Street analysts Atrys Health SA’s price is currently Undervalued.
Does Atrys Health SA pay dividends?
Atrys Health SA does not currently pay dividends.
What is Atrys Health SA’s EPS estimate?
Atrys Health SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrys Health SA have?
Atrys Health SA has 76,014,190 shares outstanding.
What happened to Atrys Health SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrys Health SA?
Currently, no hedge funds are holding shares in ES:ATRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atrys Health SA
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
ATRY Stock 12 Month Forecast
Average Price Target
€5.00
▲(66.11% Upside)
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
1nKemia IUCT Group SA
―
PRIM, S.A.
―
Labiana Health SA
―